Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
experimental group:Western medicine symptomatic treatment + Qingjin atomizing liquid atomizing treatment
control group:Western medicine symptomatic treatment + Placebo (deionized water) atomization treatment
Sponsors
The First Affiliated Hospital to Henan University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. The patient was diagnosed as severe/critical; 2. Aged >=18 years old; 3. At least 3 or more major clinical symptoms (nasal congestion or runny nose, sore throat, cough, lethargy or fatigue, myalgia or body pain, headache, chills or chills, fever, etc.) within 12 hours before screening; 4. Voluntarily accept treatment and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Dementia, all kinds of mental illness; 2. Women planning pregnancy, pregnancy and lactation; 3. Patients with active pulmonary tuberculosis, pulmonary abscess, ramus and other infectious diseases; 4. Known allergies to therapeutic medications; 5. People who are participating in clinical trials of other drugs; 6. The researchers considered unsuitable for inclusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The median duration of sustained remission of clinical symptoms;Pulmonary imaging efficacy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease outcome;Mechanical ventilation use and exit rate;Dyspnea score;Arterial blood gasblood gas measurement;Evaluation of pathogenic microorganisms;CT value of nucleic acid detection;Nucleic acid negative time;Negative conversion rate of nucleic acid; | — |
Countries
China
Contacts
Public ContactLi Suyun
The First Affiliated Hospital to Henan University of Chinese Medicine
Outcome results
None listed